Companies › Zynerba Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZYN002 Cannabidiol transdermal gel | CNR1, CNR2 | Phase 2 | Fragile X Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03802799 | ZYN002 | Phase 2 | Fragile X Syndrome | Other | Jun 2026 |
IGC Pharma Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix
Vertanical Angitia Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou Next Life Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.